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ABSTRACT
Objective: Previous studies that have found an
increased risk for tuberculosis (TB) in people with
diabetes mellitus (DM) have been conducted in
segments of the population and have not adjusted for
important potential confounders. We sought to
determine the RR for TB in the presence of DM in
a national population with data on confounding factors
in order to inform the decision-making process about
latent tuberculosis infection (LTBI) screening in people
with diabetes.
Design: Whole population historical cohort study.
Setting: All Australian States and Territories with
a mean TB incidence of 5.8/100000.
Participants: Cases of TB in people with DM were
identiﬁed by record linkage using the National Diabetes
Services Scheme Database and TB notiﬁcation
databases for the years 2001e2006.
Primary and secondary outcome
measures: Primary outcome was notiﬁed cases of
TB. Secondary outcome was notiﬁed cases of
culture-conﬁrmed TB. RR of TB was estimated with
adjustment for age, sex, TB incidence in country of
birth and indigenous status.
Results: There were 6276 cases of active TB among
19855283 people living in Australia between 2001 and
2006. There were 271 (188 culture positive) cases of
TB among 802087 members of the DM cohort and
130 cases of TB among 273023 people using insulin.
The crude RR of TB was 1.78 (95% CI 1.17 to 2.73) in
all people with DM and 2.16 (95% CI 1.19 to 3.93) in
people with DM using insulin. The adjusted RRs were
1.48 (95% CI 1.04 to 2.10) and 2.27 (95% CI 1.41 to
3.66), respectively.
Conclusions: The presence of DM alone does not
justify screening for LTBI. However, when combined
with other risk factors for TB, the presence of DM may
be sufﬁcient to justify screening and treatment for
LTBI.
INTRODUCTION
Tuberculosis (TB) continues to be a major
global health problem. It is estimated that
one-third of the world’s population have TB
infection, and there are 9.4 million new cases
of TB per year.
1 Major impairment of cell-
mediated immunity, such as occurs in HIV
infection, leads to a dramatic increase in the
risk of developing TB.
2 A lesser degree of
impairment of immune function, such as
occurs in patients with rheumatic diseases who
are on moderate-to-high dose steroid treat-
ment, has also been found to be associated
with an increased TB risk.
3 Diabetes mellitus
(DM) is a common chronic disease associated
with impaired immune function. Cohort and
case control studies have shown an association
between DM and TB.
4e9 With the rising
prevalence of DM in countries where TB is
endemic, there has been renewed interest in
the question of whether DM increases the risk
of active TB and thus could signiﬁcantly add
to the worldwide burden of disease.
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ARTICLE SUMMARY
Article focus
- National, general population-based, historical
cohort study to estimate the risk of tuberculosis
(TB) among people with diabetes mellitus (DM).
- Adjustment for important potentially confounding
risk factors including age, sex, indigenous status
and TB incidence in country of birth.
Key messages
- Overall, people with DM have a 1.5-fold
increased risk of developing TB.
- The risk for TB is higher among people who are
using insulin for DM.
- DM accounts for a small proportion of cases of
TB in a low TB incidence setting.
Strengths and limitations of this study
- The strengths of this study are the cohort design,
the large population size, the general population
base for the study cohort and the adjustment for
important potential confounders, especially TB
incidence in the country of birth.
- The study limitations are the unavailability of
laboratory results to indicate if blood glucose
levels were well or poorly controlled in people
with DM and the inability to reliably distinguish
between type 1 and type 2 DM in this data
source.
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Open Access ResearchA meta-analysis of cohort studies conducted in 2008
showed that DM was associated with an increased risk of
TB (RR 3.11, 95% CI 2.27 to 4.26).
10 However, this
ﬁnding was based on only three cohort studies, two of
which were conducted in renal transplant recipients,
who had another powerful cause of immunosuppres-
sion.
11 12 It did include one general population cohort
study, conducted among South Korean civil servants,
which identiﬁed an increased risk of TB among people
with DM.
5 Findings from caseecontrol studies were
heterogeneous with ORs ranging from 1.16 to 7.83.
10
Most of these caseecontrol studies did not measure or
control adequately for potential major confounders.
10
Hence, the ﬁndings of these caseecontrol studies may
not be a valid reﬂection of the true risk of TB in asso-
ciation with DM. Another cohort study, also from East
Asia but not included in the meta-analysis, found that
DM was associated with a modest increase in the risk of
active, culture-conﬁrmed and pulmonary TB with
adjusted HRs of 1.8, 1.9 and 1.9, respectively.
4 An
English study published in 2010 found a twofold to
threefold increased risk of TB among patients admitted
to hospital because of diabetes.
9
With the growing epidemic of obesity and DM world-
wide and continued high prevalence of TB in low-
income countries,
13 14 it is important to obtain further
data on the RR of TB in DM. We conducted a national,
general population historical cohort study to estimate
the risk of TB among people with DM with adjustment
for important potentially confounding risk factors.
METHODS
Setting and cohort
We conducted a national, general population historical
cohort study among all 19.9 million residents of
Australia, 802087 (4.0%) of whom were registered
with the National Diabetes Services Scheme (NDSS).
Australia has a low incidence of TB (5.8 per 100000
population) and 86% of all TB cases occur in overseas-
born people.
15 All TB treatment is provided free of
charge.
Description of data sources and data linkage
National Diabetes Services Scheme
People with DM were identiﬁed using the NDSS Data-
base. The NDSS is a subsidy scheme operated by Dia-
betes Australia for the Australian government. People
who are registered with the NDSS can access a range of
products including blood and urine testing strips,
syringes, needles and insulin pump consumables at
a concessional price. In order to register with the NDSS,
an individual must receive certiﬁcation of a diagnosis of
DM and, if relevant, the need for insulin therapy, from
a doctor or credentialed diabetes educator.
16 Access to
diagnostic services is enhanced by the existence of
a universal health insurance system which gives access to
primary care and other health services free of charge or
at low cost to all. People with all types of DM (type 1, type
2, gestational diabetes) are eligible for registration with
the NDSS. Diabetes type is self-reported by the patients
at the time of registration and conﬁrmed by a health
professional. We included all subjects into the analyses
that were registered with the NDSS between January
2001 and December 2006 except those with gestational
diabetes. Data on names, sex, state or territory of usual
residence, date of birth, country of birth, indigenous
status and insulin use were extracted and sent to the
database manager who performed the data linkage (see
below).
State and territory TB notiﬁcation databases
Notiﬁcation of TB is compulsory in Australia as this
notiﬁcation initiates public health investigation and
action. All TB cases are collected at State and Territory
level. We used the State and Territory TB notiﬁcation
databases to identify patients with TB. All subjects that
were notiﬁed for active TB disease to one of the State or
Territory TB notiﬁcation databases between January
2001 and December 2006 were included in our analyses.
Data on names, date of notiﬁcation, date of birth, sex,
country of birth, indigenous status and TB culture
results were extracted for this analysis.
Data linkage
People with DM who had an episode of active TB were
identiﬁed by record linkage using the NDSS Database
and the State and Territory TB notiﬁcation databases
from January 2001 to December 2006. The linkage was
performed at the Australian Institute of Health and
Welfare (AIHW). From the two data sets, match ﬁles
were created containing a unique record identiﬁer, the
data linkage items (surname, given names and date of
birth) and the data linkage check items (sex, country of
birth, state/territory of residence). From each of the
original data sets, analysis ﬁles were created containing
the unique record identiﬁer and all the data ﬁelds
required for analysis. Each of the analysis ﬁles was then
linked to the match ﬁles, and the record identiﬁers were
removed from these analysis ﬁles. The data linkage also
allowed exclusion of duplicate data on the same patient.
The data linkage protocol from the AIHW has been
published online.
17
Census data for the general population
Estimates for the distribution of age group, country of
birth, sex and indigenous status in the general popula-
tion were obtained from the Australian Bureau of
Statistics based on census data for 2006.
Sample size and study power
The annual incidence of TB in Australia is 5.8/100000.
Hence, over 6 years, the expected cumulative incidence
is 35/100000. The study population is the entire popu-
lation of Australia, that is, 20 million people. We esti-
mated that there were 1000000 persons with diabetes.
The study had 80% power to detect a RR of 1.16 or
higher.
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Tuberculosis in diabetesStatistical analysis
Only cases of TB that were notiﬁed after DM was diag-
nosed were included. The follow-up period started from
1 January 2001 or the date of DM diagnosis, whichever
was the later and continued until 31 December 2006 or
the date of diagnosis of TB, whichever was the earlier. TB
incidence rates were expressed per 100000 person-years
of follow-up with asymptotic 95% CIs.
18
The RR of TB in patients with DM was estimated using
a log-binomial model with correction for overdispersion
to prevent underestimation of SEs due to heterogeneity
in the data. The model was adjusted for TB incidence in
country of birth, sex, age and indigenous status. Indi-
vidual-level data on these potential confounders were
available for the DM and TB cohorts. For the general
population, aggregate population data for these cova-
riates were obtained from the Australian Bureau of
Statistics in the form of a contingency table containing
population numbers cross-classiﬁed by all possible
combinations of strata of the covariates listed above. Age
was classiﬁed into 5-year age groups, and country of birth
was aggregated to groupings of countries with a similar
incidence of TB (<10, 10e24, 25e49, 50e99, 100e299
and $300/100000) based on published WHO data.
19
Population attributable fraction was estimated using
the formula: (Pe 3 (RR  1))/((Pe 3 (RR  1) + 1),
where RR is the RR, estimated as above, and Pe is the
proportion of the population exposed to the risk factor,
that is, the prevalence of DM in the population.
20
We performed planned sub-group analyses based on
insulin treatment status and TB culture status. In addition,
interactions between DM status and age, sex, indigenous
status and TB incidence in country of birth were tested.
All statistical analyses were carried out using SAS
Statistical Software (V.9.2) (SAS Institute).
Ethical approval
The study protocol was approved by the Sydney South
West Area Health Service Human Research Ethics
CommitteedWestern Zone, the New South Wales
Population & Health Services Research Ethics
Committee, the AIHW Ethics Committee, the Queens-
land Health Research Ethics & Governance Unit, the
Department of Human Services Victoria Research
Governance, the Australian Capital Territory Health
Human Research Ethics Committee, the Department of
Health Western Australia Human Research Ethics
Committee, the Tasmania Health and Medical Human
Research Ethics Committee and the South Australia
Department of Health Human Research Ethics
Committee and the Northern Territory Human Research
Ethics Committee. The requirement for written or verbal
patients’ consent for this data linkage study was waived
by all of the above ethics committees because existing
data sources were used.
RESULTS
The study population comprised 19855283 residents of
Australia, 802087 (4%) of whom were registered with
the NDSS including 273023 (1.4%) with DM who were
using insulin. Characteristics of the DM population, the
general population, the TB population and the DM
population with TB are shown in table 1. The percentage
of Australian-born people was slightly higher in the DM
population than in the general population (74% vs
71%), and more people came from an area with a TB
incidence below 25/100000 (92% vs 84%). The mean
duration of follow-up was 4.6 years.
There were 6276 TB notiﬁcations (5.7/100000/year,
95% CI 5.5 to 5.8) in Australia during the study period
(table 2). There were 271 cases of TB among 802087
members of the DM cohort (7.4/100000/year, 95% CI
6.5 to 8.3). Of these, 188 (69%) were culture positive,
which is similar to the 70% culture positive cases among
all TB notiﬁcations. There were 130 TB notiﬁcations
among 273023 people using insulin (9.1/100000/year,
95% CI 7.6 to 10.9).
The crude RR of TB was 1.78 (95% CI 1.17 to 2.73) in
all people with DM and 2.16 (95% CI 1.19 to 3.93) in
people with DM using insulin. In the multivariate anal-
ysis adjusted for age, TB incidence in country of birth,
indigenous status and sex, the RR of TB was 1.48 (95%
CI 1.04 to 2.10) in all people with DM and 2.27 (95% CI
1.41 to 3.66) in people using insulin (table 3). The
estimates of RR were slightly higher when the analysis
was limited to culture-conﬁrmed cases of TB (table 3).
The RRs were not signiﬁcantly modiﬁed by age group,
indigenous status, sex or incidence in country of birth
(all p values for interaction >0.25).
The population attributable fraction of DM for TB was
1.7%, based on a diabetes prevalence of 3.6%.
21
DISCUSSION
In this large, population-based cohort study conducted
in 19.9 million residents of Australia with adjustment
for important confounding factors, we found that,
overall, people with DM have a 1.5-fold increased risk of
developing TB. Those who are using insulin for DM
have a greater risk. We also found that the population
attributable fraction of DM for TB was very small.
The results of our study extend the ﬁndings of
previous studies, which have also observed an increased
risk for TB in patients with DM. A cohort study in Hong
Kong, limited to people aged 65 years or more, found an
adjusted HR (aHR) of 1.77 (95% CI 1.41 to 2.24) for
active TB and an aHR of 1.91 (95% CI 1.45 to 2.52) for
culture-conﬁrmed TB among patients with DM.
4
However, this study found that people with diagnosed
DM and with haemoglobin HbA1c <7% at enrolment
were not at increased risk of TB (aHR 0.68, 95% CI 0.33
to 1.36). A Korean cohort study conducted in 790000
civil servants found a RR of 3.47 (95% CI 2.98 to 4.03)
for pulmonary TB in people with DM and a RR of 5.15
for culture-conﬁrmed cases (95% CI 3.82 to 6.94).
5 In
the Korean study, a diagnosis of DM was based solely on
blood glucose levels. Thus, it did not include diabetic
subjects who were euglycaemic at the time of screening.
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Tuberculosis in diabetesIn their systematic review on 13 observational studies on
the risk of DM in TB, Jeon and Murray
10 found that
studies which used laboratory testing as the basis for the
diagnosis of DM had a higher RR for TB than those that
used self-reporting or medical records (RR of 3.89, 2.26
and 1.61, respectively). If blood glucose levels are used
for the deﬁnition of DM, patients with diabetes who have
well-controlled glucose levels are less likely to be
included. These ﬁndings imply that hyperglycaemia,
rather than a DM diagnosis per se, increases the risk of
developing active TB. This is supported by the observa-
tion by Leung et al
4 that patients with poor recent
glycaemic control as evidenced by a haemoglobin HbA1c
$7% had a signiﬁcantly increased risk of TB (adjusted
HR (aHR) 2.56, 95% CI 1.95 to 3.35), while those with
a haemoglobin HbA1c <7% did not (aHR 0.81, 95% CI
0.44 to 1.48). In our study, DM diagnosis was based on
self-reporting conﬁrmed by a health professional, and
laboratory results were not available. As insulin use is
often a marker of longer duration and/or poorly
controlled (type 2) DM, our ﬁnding that insulin users
had a higher TB risk than the whole diabetes cohort
Table 1 Characteristics of the general population, the DM population, the TB population and the TB in DM population
Variable
General population excluding
people with diabetes
(n[19053196)
DM population
(n[802087)
TB population
(n[6276)
TB in DM
population
(n[271)
Gender, n (%)
Female 9669609 (51) 386427 (48) 3045 (49) 122 (45)
Male 9383587 (49) 415660 (52) 3231 (51) 149 (55)
Age group in years, n (%)
<15 3931189 (21) 6024 (1) 272 (4) 0
15e34 5341173 (28) 39482 (5) 2220 (35) 10 (4)
35e54 5526963 (29) 173391 (21) 1729 (28) 56 (21)
55e74 3199578 (17) 366534 (46) 1176 (19) 123 (45)
$75 1054293 (6) 216656 (27) 879 (14) 82 (30)
Country of origin, n (%)
Australian born 13477425 (71) 595518 (74) 1212 (19) 131 (48)
Born overseas 4209464 (22) 206569 (26) 5064 (81) 140 (52)
Unknown 1366307 (7) 0 0 0
Indigenous status, n (%)
Non-indigenous or not stated 18622238 (98) 780197 (97) 6072 (97) 265 (98)
Indigenous 430958 (2) 21890 (3) 204 (3) 6 (2)
TB incidence in country of birth (per 100000), n (%)
<25 16052757 (84) 739423 (92) 1964 (31) 168 (62)
25e99 848417 (4) 36292 (5) 1350 (22) 44 (16)
$100 728119 (4) 26372 (3) 2962 (47) 59 (22)
Unknown 1423903 (7) 0 0 0
TB, tuberculosis.
Table 2 Crude incidence of TB in the general population and in people with diabetes
Incidence of all TB per 100000/year (95% CI)
Incidence of culture positive TB per
100000/year (95% CI)
General population People with diabetes General population People with diabetes
All persons 5.7 (5.5 to 5.8) 7.4 (6.5 to 8.3) 4.0 (3.9 to 4.1) 5.1 (4.4 to 5.9)
Age, years
<15 1.2 (1.1 to 1.4) 0 0.4 (0.3 to 0.5) 0
15e34 7.4 (7.1 to 7.7) 6.1 (3.1 to 11.7) 5.5 (5.2 to 5.8) 4.3 (1.9 to 9.3)
35e54 5.5 (5.2 to 5.7) 7.5 (5.8 to 9.9) 3.9 (3.7 to 4.1) 5.5 (4.0 to 7.6)
55e74 6.0 (5.6 to 6.3) 7.4 (6.2 to 8.9) 4.1 (3.8 to 4.4) 4.9 (3.9 to 6.1)
$75 13.0 (12.1 to 13.9) 7.5 (6.0 to 9.4) 9.7 (9.0 to 10.5) 5.4 (4.2 to 7.0)
Sex
Male 5.9 (5.7 to 6.2) 7.9 (6.7 to 9.3) 4.3 (4.1 to 4.5) 5.4 (4.4 to 6.6)
Female 5.4 (5.2 to 5.6) 6.9 (5.7 to 8.3) 3.7 (3.6 to 4.9) 4.9 (3.9 to 6.0)
TB incidence in country of birth
<25/100000 1.95 (1.86 to 2.04) 4.9 (4.2 to 5.7) 1.26 (1.20 to 1.34) 3.4 (2.8 to 4.1)
25e99/100000 25.5 (24.1 to 26.9) 30.1 (22.1 to 40.8) 18.0 (16.9 to 19.2) 18.5 (12.4 to 27.3)
$100/100000 65.4 (63.1 to 67.8) 57.8 (44.4 to 75.0) 48.8 (46.8 to 50.9) 45.0 (33.3 to 60.6)
TB, tuberculosis.
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Tuberculosis in diabeteswould support the assumption that hyperglycaemia
increases the risk for developing active TB. However, as
we did not have any data on duration of DM or HbA1C
levels, and people with type I diabetes were included in
the insulin-treated group, it remains unclear whether
insulin use is an independent risk factor for TB or
a proxy for longer duration or greater severity of DM.
Age did not modify the effect of DM on risk of TB in
our study. Two published studies have demonstrated
stronger associations of DM with TB among people aged
less than 40 years compared with older people.
5 8 In
these studies, the deﬁnition of DM cases was based on
laboratory results. Another study, which had a DM
diagnosis based on medical records, did not show the
same trend for age.
22
Interestingly, there is some evidence that the strength
of the association of DM and TB increases with
increasing background TB incidence in the study
population.
7 10 This trend was found in a systematic
review on the risk of TB in DM in 13 observational
studies
10 and in a Texan study that found that the asso-
ciation was stronger for the population in the Texas
border region, where there are higher incidence rates of
TB, compared with non-border counties.
7 The reason
for this observation is not entirely clear, but it could well
relate to the level of glucose control in patients with DM
in settings with a high TB incidence.
The strengths of our study are the cohort design, the
large population size and the general population base
for the study cohort. We believe that the diabetes cohort
represents a virtually complete cohort of patients with
diagnosed diabetes in Australia. The Australian Diabetes,
Obesity and Lifestyle Study (1999e2000), which
included previously undiagnosed cases identiﬁed by
blood glucose estimations, estimated that 950000
persons aged 25 years and over had diabetes.
23 The
National Health Survey 2004e2005 found that 700000
(3.6%) Australians identiﬁed themselves as having DM.
21
In the same period, 733000 (3.6%) Australians with
a certiﬁed diagnosis of DM were registered with the
NDSS.
21 On the basis of these and other data, Diabetes
Australia estimates that the NDSS covers 80%e90% of
people with diagnosed DM.
21 The AIHW has identiﬁed
the NDSS as one of the best available sources for moni-
toring the prevalence of diagnosed DM in Australia,
based on coverage of the DM population, currency of
the data source and frequency of updates to the data
source.
21 However, we acknowledge that the ﬁndings of
this study may not be generalisable to people with
undiagnosed DM, who may have an elevated risk of TB
compared with those truly without diabetes.
Ascertainment of cases of TB is likely to be complete.
TB is a notiﬁable disease in Australia and notiﬁcation by
hospitals, doctors, TB clinics and pathology laboratories
leads to public health action. The rate of undiagnosed
TB in Australia is assumed to be very low as all investi-
gations and treatment related to TB are provided free of
charge for everybody, independent of insurance and
immigration status, thus lowering the threshold to access
care.
An additional strength of this study is the adjustment
for important potential confounders, especially for the
TB incidence in the country of birth. The incidence of
TB in the country of birth is one of the strongest
predictors of the risk of developing TB, but none of the
previously published studies had adjusted the RR for this
important confounder.
10 This adjustment is especially
important for settings with a low incidence of TB, where
the majority of TB cases usually occur in foreign-born
people.
24 The adjustment for the incidence of TB in
country of birth also makes the study results general-
isable to populations with varying incidence of TB.
Our study has some limitations. As outlined above,
laboratory results were not available to indicate if blood
glucose levels were well or poorly controlled in people
with DM. However, the diagnosis of DM in this study
population is robust as all individuals registered with the
NDSS must receive certiﬁcation of a diagnosis of DM by
a doctor or a credentialed diabetes educator. The avail-
able data did not allow us to reliably distinguish between
type 1 and type 2 DM. It did allow us to reliably distin-
guish between patients treated with insulin and those
not treated with insulin.
Although, as described above, we did adjust for
potential confounding due to the major risk factors for
TB in Australia, we did not have information on socio-
economic status, which may have been a confounding
factor in this setting. A limitation that this study shares
with previously published papers in this area is that we
did not have any information on treatment of latent
tuberculosis infection (LTBI) in the NDSS cohort.
However, routine assessment and treatment for LTBI in
patients with diabetes is currently not recommended in
Australia, and it can therefore be assumed that most
people with diabetes would not have been assessed and
treated for LTBI.
Table 3 RRs (crude and adjusted) for different TB end points
Characteristics
Crude RR univariate
analysis (95% CI) p Value
Adjusted RR* multivariate
analysis (95% CI) p Value
All TB 1.78 (1.17 to 2.73) 0.008 1.48 (1.04 to 2.10) 0.03
Culture-positive TB 1.83 (1.19 to 2.81) 0.006 1.49 (1.05 to 2.11) 0.02
All TB in insulin users 2.16 (1.19 to 3.93) 0.01 2.27 (1.41 to 3.66) 0.0008
Culture-positive TB in insulin users 2.44 (1.37 to 4.34) 0.002 2.55 (1.62 to 4.01) <0.001
*Adjusted for sex, age, indigenous status and TB incidence in country of birth.
TB, tuberculosis.
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Tuberculosis in diabetesCONCLUSIONS
DM is associated with a modest increase in the risk of
developing TB. The risk is greater among those treated
with insulin for diabetes. Based on this modest RR, the
presence of DM alone does not justify screening for, and
treatment of, LTBI. However, when combined with other
risk factors for TB, the presence of DM may be sufﬁcient
to justify screening and treatment for LTBI. The low
population attributable risk, at least in Australia, suggests
that control of TB in people with DM is unlikely to
make a major contribution to the burden of TB in the
population.
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